---
title: "Sino Biopharm Wins NMPA Nod for Innovative Hepatitis B Drug Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293596941.md"
description: "Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, received approval from China’s NMPA to initiate clinical trials for IM-101, a novel Category 1 drug for chronic hepatitis B. Designed to restore immune responses and aim for functional cures, IM-101 addresses limitations of current treatments. This development strengthens Sino Biopharm’s liver disease pipeline, which includes late-stage assets and collaborations with GSK. The company currently holds a 'Buy' rating with a HK$7.80 price target."
datetime: "2026-07-23T10:09:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293596941.md)
  - [en](https://longbridge.com/en/news/293596941.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293596941.md)
generator: "portal-rs"
---

# Sino Biopharm Wins NMPA Nod for Innovative Hepatitis B Drug Trial

Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.

Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration to begin clinical trials of IM-101, a PreS1 recombinant fusion protein developed as a national Category 1 innovative drug for chronic hepatitis B. IM-101 is designed to break immune tolerance and restore HBV-specific immune responses, aiming for a functional cure by combining humoral and cellular mechanisms to neutralise viral particles, prevent reinfection and clear infected hepatocytes.

The company underscores that current hepatitis B treatments, such as nucleos(t) ide analogues and interferons, achieve low rates of functional cure and often require long-term therapy, highlighting the unmet need IM-101 seeks to address. The new candidate further strengthens Sino Biopharmaceutical’s liver disease pipeline, which includes late-stage assets like lanifibranor and TQA3605, Phase II agents targeting TLR-7 and THR, and a strategic collaboration with GSK on Bepirovirsen, positioning the group as a leading player in functional cure strategies for chronic hepatitis B and related liver conditions.

The most recent analyst rating on (HK:1177) stock is a Buy  
 with a HK$7.80 price target.  
 To see the full list of analyst forecasts on Sino Biopharmaceutical stock,  
 see the HK:1177 Stock Forecast page. 

**More about Sino Biopharmaceutical**

Sino Biopharmaceutical is a China-focused pharmaceutical company with a strong presence in liver disease treatments, particularly chronic hepatitis B and metabolic dysfunction-associated steatohepatitis. Its portfolio and pipeline span antiviral agents, immunotherapies and metabolic drugs, with multiple candidates in Phase II and III trials and strategic partnerships to accelerate innovative therapies in China.

**Average Trading Volume:** 98,569,235

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$90.99B

For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md)
- [Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trial](https://longbridge.com/en/news/296603125.md)
- [Key facts: Jemperli BLA Accepted for GSK; Hibsago Approved in Japan](https://longbridge.com/en/news/296749168.md)
- [REG - GSK PLC - First global approval for Hibsago in Japan](https://longbridge.com/en/news/296742819.md)
- [GSK: FDA Accepts SBLA For Jemperli With Priority Review](https://longbridge.com/en/news/296744801.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**